Supernatural T cells: Genetic modification of T cells for cancer therapy

被引：127

作者：

Kershaw, MH ^{[1
]}

Teng, MWL ^{[1
]}

Smyth, MJ ^{[1
]}

Darcy, PK ^{[1
]}

机构：

[1] Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia

来源：

NATURE REVIEWS IMMUNOLOGY | 2005年 / 5卷 / 12期

基金：

英国医学研究理事会;

关键词：

D O I：

10.1038/nri1729

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunotherapy is receiving much attention as a means of treating cancer, but complete, durable responses remain rare for most malignancies. The natural immune system seems to have limitations and deficiencies that might affect its ability to control malignant disease. An alternative to relying on endogenous components in the immune repertoire is to generate lymphocytes with abilities that are greater than those of natural T cells, through genetic modification to produce 'supernatural' T cells. This Review describes how such T cells can circumvent many of the barriers that are inherent in the tumour microenvironment while optimizing T-cell specificity, activation, homing and antitumour function.

引用

页码：928 / 940

页数：13

共 129 条

[1]

Altenschmidt U, 1997, J IMMUNOL, V159, P5509

[2] Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells [J].

Amsen, D ;

Blander, JM ;

Lee, GR ;

Tanigaki, K ;

Honjo, T ;

Flavell, RA .

CELL, 2004, 117 (04) :515-526

[3] A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells [J].

Andersen, PS ;

Stryhn, A ;

Hansen, BE ;

Fugger, L ;

Engberg, J ;

Buus, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (05) :1820-1824

[4] Role of T cell costimulation in anti-viral immunity [J].

Bertram, EM ;

Dawicki, W ;

Watts, TH .

SEMINARS IN IMMUNOLOGY, 2004, 16 (03) :185-196

[5] Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity [J].

Bollard, CM ;

Rössig, C ;

Calonge, MJ ;

Huls, MH ;

Wagner, HJ ;

Massague, J ;

Brenner, MK ;

Heslop, HE ;

Rooney, CM .

BLOOD, 2002, 99 (09) :3179-3187

[6] Safety of retroviral gene marking with a truncated NGF receptor [J].

Bonini, C ;

Grez, M ;

Traversari, C ;

Ciceri, F ;

Marktel, S ;

Ferrari, G ;

Dinauer, M ;

Sadat, M ;

Aiuti, A ;

Deola, S ;

Radrizzani, M ;

Hagenbeek, A ;

Apperley, J ;

Ebeling, S ;

Martens, A ;

Kolb, HJ ;

Weber, M ;

Lotti, F ;

Grande, A ;

Weissinger, E ;

Bueren, JA ;

Lamana, M ;

Falkenburg, JHF ;

Heemskerk, MHM ;

Austin, T ;

Kornblau, S ;

Marini, F ;

Benati, C ;

Magnani, Z ;

Cazzaniga, S ;

Toma, S ;

Gallo-Stampino, C ;

Introna, M ;

Slavin, S ;

Greenberg, PD ;

Bregni, M ;

Mavilio, F ;

Bordignon, C .

NATURE MEDICINE, 2003, 9 (04) :367-369

[7] HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].

Bonini, C ;

Ferrari, G ;

Verzeletti, S ;

Servida, P ;

Zappone, E ;

Ruggieri, L ;

Ponzoni, M ;

Rossini, S ;

Mavilio, F ;

Traversari, C ;

Bordignon, C .

SCIENCE, 1997, 276 (5319) :1719-1724

[8] Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 [J].

Brentjens, RJ ;

Latouche, JB ;

Santos, E ;

Marti, F ;

Gong, MC ;

Lyddane, C ;

King, PD ;

Larson, S ;

Weiss, M ;

Rivière, I ;

Sadelain, M .

NATURE MEDICINE, 2003, 9 (03) :279-286

[9] Massive expansion of antigen-specific CD8+ T cells during an acute virus infection [J].

Butz, EA ;

Bevan, MJ .

IMMUNITY, 1998, 8 (02) :167-175

[10] A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia [J].

Cathcart, K ;

Pinilla-Ibarz, J ;

Korontsvit, T ;

Schwartz, J ;

Zakhaleva, V ;

Papadopoulos, EB ;

Scheinberg, DA .

BLOOD, 2004, 103 (03) :1037-1042

← 1 2 3 4 5 6 7 8 9 10 →